bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental legend from Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors
Authors: Subbiah Vivek , Grilley-Olson Juneko E. , Combest Austin J. , Sharma Neelesh , Tran Richard H. , Bobe Iulian , Osada Atsushi , Takahashi Kazuhiro , Balkissoon Jaikrishna , Camp Aaron , Masada Atsuhiro , Reitsma Dirk J. , Bazhenova Lyudmila A.
Published: April 2023

Supplemental legend
Supplementary Figure S4. Cell proliferation inhibition of FASN inhibitors EGCG and C75 in doxorubicin resistant cells from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Authors: Giró-Perafita Ariadna , Palomeras Sònia , Lum David H. , Blancafort Adriana , Viñas Gemma , Oliveras Glòria , Pérez-Bueno Ferran , Sarrats Ariadna , Welm Alana L. , Puig Teresa
Published: April 2023

(A) 231 and 231DXR cells were treated with increasing concentrations of EGCG ( 100 - 200 µM) or C75 (30 - 90 µM) for 48h. (B) HCC and HCCDXR cells were treated with increasing concentrations of EGCG ( 100 - 250 µM) or C75 (20 - 60 µM) for 48h. Results are expressed as mean {plus minus} SEM. Experiments were performed at least three times in triplicate.
Figure S4 from Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Authors: Li Si , Siriwon Natnaree , Zhang Xiaoyang , Yang Shuai , Jin Tao , He Feng , Kim Yu Jeong , Mac John , Lu Zhengfei , Wang Sijie , Han Xiaolu , Wang Pin
Published: April 2023

(A) The blocking activity of anti-PD-1 scFv on the binding of PD-1 detection antibody. Human T cells were activated with anti-CD3/CD28 beads for 48 hours and then cultured in TCM supplemented with 10 ng/ml of human IL-2 for two weeks. The activated T cells were then incubated with 1 ml of CAR19.Î±PD1 T cell culture supernatant or control medium for 30 min. The T cells were washed once with PBS and then stained with anti-PD-1 antibody. (B) The relative transcriptional expression of PD-1 on CAR19 and CAR19.Î±PD1 T cells upon antigen-specific stimulation for 24 hours (n = 3, mean {plus minus} SEM; ***P<0.001).
Supplemental Figures from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Authors: Wang Xiuli , Walter Miriam , Urak Ryan , Weng Lihong , Huynh Christian , Lim Laura , Wong ChingLam W. , Chang Wen-Chung , Thomas Sandra H. , Sanchez James F. , Yang Lu , Brown Christine E. , Pichiorri Flavia , Htut Myo , Krishnan Amrita Y. , Forman Stephen J.
Published: April 2023

Supplemental Figure 1. High dose CS1 CAR T cells were not able to prevent tumor relapse Supplemental Figure 2. Soluble CS1 does not interfere with CS1 CAR function Supplemental Figure 3. Lenalidomide preferentially expanded CD8+CAR+ T cells in a dosedependent manner Supplemental Figure 4. Lenalidomide decreased CD4+ T cell expansion in a dose-dependent manner Supplemental Figure 5. Lenalidomide eradicated MM-initiating cells without downregulation of CS1 expression on MM cells Supplemental Figure 6. Lenalidomide improves immune synapse formation between CS1 CAR T cells and MM cells Supplemental Figure 7. Lenalidomide improved the anti-MM activity of CS1 CAR T cells Supplemental Figure 8. Comparison of anti-MM activity of CS1 CAR T cells pre-treated with and without lenalidomide Supplemental Figure 9. Lenalidomide enhances CS1 CAR T cell function only when continuous combinatorial therapy is applied
Supplementary figures and tables from Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring
Authors: Kang Zhigang , Stevanović Sanja , Hinrichs Christian S. , Cao Liang
Published: April 2023

Fig. S1. E7 sequence alignments of HPV 16 variants and HPV18 variants for ddPCR assay design Fig. S2. ddPCR dual detection assay for HPV 16 and HPV18 with genomic DNA from cervical cancer cell lines Fig. S3. Dilution linearity and quantification range with HPV DNA spiked plasma samples Fig. S4. Cervical cancer patient blood HPV genotyping for 14 HPV types Table S1. Record on healthy blood donors Table S2. HPV variants covered by the HPV16 and HPV18 specific detection assays Table S3. Sequences of ddPCR primers and probes used for HPV16 and HPV18 ccfDNA detection Table S4. Interference study with plasma containing potential interferents and spiked HPV16 DNA
Supplementary Table S3 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Authors: Hahn Noah M. , Bivalacqua Trinity J. , Ross Ashley E. , Netto George J. , Baras Alex , Park Jong Chul , Chapman Carolyn , Masterson Timothy A. , Koch Michael O. , Bihrle Richard , Foster Richard S. , Gardner Thomas A. , Cheng Liang , Jones David R. , McElyea Kyle , Sandusky George E. , Breen Timothy , Liu Ziyue , Albany Costantine , Moore Marietta L. , Loman Rhoda L. , Reed Angela , Turner Scott A. , De Abreu Francine B. , Gallagher Torrey , Tsongalis Gregory J. , Plimack Elizabeth R. , Greenberg Richard E. , Geynisman Daniel M.
Published: April 2023

Supplementary Table S3: Baseline Tumor pFGFR3 IHC Intensity
Supplementary FiguresS1-5 from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Authors: Herman Sarah E.M. , Montraveta Arnau , Niemann Carsten U. , Mora-Jensen Helena , Gulrajani Michael , Krantz Fanny , Mantel Rose , Smith Lisa L. , McClanahan Fabienne , Harrington Bonnie K. , Colomer Dolors , Covey Todd , Byrd John C. , Izumi Raquel , Kaptein Allard , Ulrich Roger , Johnson Amy J. , Lannutti Brian J. , Wiestner Adrian , Woyach Jennifer A.
Published: April 2023

Supplementary Figure S1: Acalabrutinib is a more potent BCR-inhibitor than ibrutinib in vivo at 1mg/kg and 3mg/kg. Supplementary Figure S2: In vivo gating strategy for murine cells. Supplementary Figure S3: In vivo acalabrutinib treatment inhibits BCR signal transduction similarly to ibrutinib. Supplementary Figure S4: In vitro gating strategy for patient MNCs.
Supplementary Figure Legends from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Authors: Herman Sarah E.M. , Montraveta Arnau , Niemann Carsten U. , Mora-Jensen Helena , Gulrajani Michael , Krantz Fanny , Mantel Rose , Smith Lisa L. , McClanahan Fabienne , Harrington Bonnie K. , Colomer Dolors , Covey Todd , Byrd John C. , Izumi Raquel , Kaptein Allard , Ulrich Roger , Johnson Amy J. , Lannutti Brian J. , Wiestner Adrian , Woyach Jennifer A.
Published: April 2023

Supplementary Figure S5: Acalabrutinib demonstrates similar changes in proliferation and tumor burden in the CLL xenograft mouse model as ibrutinib.
Figure S2 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Authors: Canella Alessandro , Welker Alessandra M. , Yoo Ji Young , Xu Jihong , Abas Fazly S. , Kesanakurti Divya , Nagarajan Prabakaran , Beattie Christine E. , Sulman Erik P. , Liu Joseph , Gumin Joy , Lang Frederick F. , Gurcan Metin N. , Kaur Balveen , Sampath Deepa , Puduvalli Vinay K.
Published: April 2023

Figure S1
Supplementary Table 2 from Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
Authors: Mouw Kent W. , Cleary James M. , Reardon Brendan , Pike Jonathan , Braunstein Lior Z. , Kim Jaegil , Amin-Mansour Ali , Miao Diana , Damish Alexis , Chin Joanna , Ott Patrick A. , Fuchs Charles S. , Martin Neil E. , Getz Gad , Carter Scott , Mamon Harvey J. , Hornick Jason L. , Van Allen Eliezer M. , D'Andrea Alan D.
Published: April 2023

Supplementary Table 2
Figure S1 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Authors: Canella Alessandro , Welker Alessandra M. , Yoo Ji Young , Xu Jihong , Abas Fazly S. , Kesanakurti Divya , Nagarajan Prabakaran , Beattie Christine E. , Sulman Erik P. , Liu Joseph , Gumin Joy , Lang Frederick F. , Gurcan Metin N. , Kaur Balveen , Sampath Deepa , Puduvalli Vinay K.
Published: April 2023

Figure S1
Supplementary Table S3 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

Combination of niclosamide and imatinib eliminated LSCs in vitro.
Supplementary Table S2 from Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
Authors: Yokoyama Shintaro , Miyoshi Hiroaki , Nakashima Kazutaka , Shimono Joji , Hashiguchi Toshihiro , Mitsuoka Masahiro , Takamori Shinzo , Akagi Yoshito , Ohshima Koichi
Published: April 2023

Supplementary Table S2. Multivariate analysis for prognostic factors affecting overall survival
Supplementary Table S1 from Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
Authors: Yokoyama Shintaro , Miyoshi Hiroaki , Nakashima Kazutaka , Shimono Joji , Hashiguchi Toshihiro , Mitsuoka Masahiro , Takamori Shinzo , Akagi Yoshito , Ohshima Koichi
Published: April 2023

Supplementary Table S1. Patient characteristics
Supplementary Table S1 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

Primers for ChIP and qPCR.
Supplementary Figure S3 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

Increased expression of p65, FOXM1 and β-catenin in human CML stem cells.
Table S1 from Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics
Authors: Yan Yuanqing , Gao Ruli , Trinh Thao L.P. , Grant Maria B.
Published: April 2023

Table S1 lists the differentially expressed genes
Supplementary Data from Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer
Authors: Scurr Martin , Pembroke Tom , Bloom Anja , Roberts David , Thomson Amanda , Smart Kathryn , Bridgeman Hayley , Adams Richard , Brewster Alison , Jones Robert , Gwynne Sarah , Blount Daniel , Harrop Richard , Hills Robert , Gallimore Awen , Godkin Andrew
Published: April 2023

Supplementary Figure 1. CONSORT diagram. Supplementary Figure 2. 5T4 peptide pools and matrix system. Supplementary Figure 3. B-cell number in response to cyclophosphamide. Supplementary Figure 4. Expression of activation markers in T-cell subsets during CPM treatment. Supplementary Figure 5. Immunological responses following the completion of CPM treatment. Supplementary Figure 6. Analysis of immunological responses over 8 courses of CPM in patient 102.
Supplementary Materials from Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI
Authors: Nie Ke , Shi Liming , Chen Qin , Hu Xi , Jabbour Salma K. , Yue Ning , Niu Tianye , Sun Xiaonan
Published: April 2023

Supplementary Table 1: All 103 imaging feature (mean{plus minus}standard deviation[range] ) between pCR vs. non-pCR groups. Supplementary Table 2: All 103 imaging feature (mean{plus minus}standard deviation[range] ) between GR vs. non-GR groups.
Tables S1 - 5 from Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML
Authors: Reichenbach Frank , Wiedenmann Cornelius , Schalk Enrico , Becker Diana , Funk Kathrin , Scholz-Kreisel Peter , Todt Franziska , Wolleschak Denise , Döhner Konstanze , Marquardt Jens U. , Heidel Florian , Edlich Frank
Published: April 2023

S1 BAX/BAK localization for the test cohort S2 clinical characterization of patient cohorts S3 GISTIC analysis of the test cohort S4 BAX/BAK localization for the validation cohort S5 Multivariate analysis of variance for human AML survival probablity
Table S3 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
Authors: Yi John S. , Ready Neal , Healy Patrick , Dumbauld Chelsae , Osborne Robyn , Berry Mark , Shoemaker Debra , Clarke Jeffrey , Crawford Jeffrey , Tong Betty , Harpole David , D'Amico Thomas A. , McSherry Frances , Dunphy Frank , McCall Shannon J. , Christensen Jared D. , Wang Xiaofei , Weinhold Kent J.
Published: April 2023

Signed-Rank Tests of V3-V2 Difference
Table S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
Authors: Yi John S. , Ready Neal , Healy Patrick , Dumbauld Chelsae , Osborne Robyn , Berry Mark , Shoemaker Debra , Clarke Jeffrey , Crawford Jeffrey , Tong Betty , Harpole David , D'Amico Thomas A. , McSherry Frances , Dunphy Frank , McCall Shannon J. , Christensen Jared D. , Wang Xiaofei , Weinhold Kent J.
Published: April 2023

List of antibodies used for flow cytometry analysis
Supplementary figures legends from Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer
Authors: Francica Paola , Nisa Lluís , Aebersold Daniel M. , Langer Rupert , Bladt Friedhelm , Blaukat Andree , Stroka Deborah , Martínez María Rodríguez , Zimmer Yitzhak , Medová Michaela
Published: April 2023

Supplementary figures legends
Supplementary figures 1-6 from Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer
Authors: Francica Paola , Nisa Lluís , Aebersold Daniel M. , Langer Rupert , Bladt Friedhelm , Blaukat Andree , Stroka Deborah , Martínez María Rodríguez , Zimmer Yitzhak , Medová Michaela
Published: April 2023

Supplementary figure 1. A, Representative two-parameter flow diagrams (BrdU uptake versus DNA content) of the BrdU proliferation assay; Supplementary figure 2. A, GTL-16 tumor xenograft growth as monitored daily by caliper measurements (METi - days 1-6; IR - day 3); Supplementary figure 3. Total KATO-II cellular protein extracts were subjected to western blotting with a specific antibody against p-p53, p53, p21 or p16 following the indicated treatments; Supplementary figure 4. A, representative images (40x magnification) of SA-βGal activity in MKN-45, SNU-5 and KATO-II cells; Supplementary figure 5. Western blot analysis showing FOXM1 total levels and following MET, MEK or PI3K inhibition; Supplementary figure 6. A, GTL-16 overexpressing FOXM1 cells (clone 1 and 2) and empty vector GTL-16 cells were subjected to western blotting using specific antibodies against FOXM1, BRIP and yH2AX following the indicated treatments.
Supplementary Table S1: Breast cancer sequencing studies from Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer
Authors: Yates Lucy R. , Desmedt Christine
Published: April 2023

Overview of breast cancer sequencing studies.
Supplemental Figure S1 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Figure S1: ARID1A loss activates PI3K/AKT and has no effect on MAPK/ERK signaling in BT474 cells
Table S4 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Authors: Pierobon Mariaelena , Ramos Corinne , Wong Shukmei , Hodge K. Alex , Aldrich Jessica , Byron Sara , Anthony Stephen P. , Robert Nicholas J. , Northfelt Donald W. , Jahanzeb Mohammad , Vocila Linda , Wulfkuhle Julia , Gambara Guido , Gallagher Rosa I. , Dunetz Bryant , Hoke Nicholas , Dong Ting , Craig David W. , Cristofanilli Massimo , Leyland-Jones Brian , Liotta Lance A. , O'Shaughnessy Joyce A. , Carpten John D. , Petricoin Emanuel F.
Published: April 2023

AKT S473 distribution based on ER, HER2 expression measured by IHC in for primary and metastatic lesions included in the validation set.
Supplementary legend from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Authors: Seed George , Yuan Wei , Mateo Joaquin , Carreira Suzanne , Bertan Claudia , Lambros Maryou , Boysen Gunther , Ferraldeschi Roberta , Miranda Susana , Figueiredo Ines , Riisnaes Ruth , Crespo Mateus , Rodrigues Daniel Nava , Talevich Eric , Robinson Dan R. , Kunju Lakshmi P. , Wu Yi-Mi , Lonigro Robert , Sandhu Shahneen , Chinnaiyan Arul M. , de Bono Johann S.
Published: April 2023

Supplementary legend
Table S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Authors: Pierobon Mariaelena , Ramos Corinne , Wong Shukmei , Hodge K. Alex , Aldrich Jessica , Byron Sara , Anthony Stephen P. , Robert Nicholas J. , Northfelt Donald W. , Jahanzeb Mohammad , Vocila Linda , Wulfkuhle Julia , Gambara Guido , Gallagher Rosa I. , Dunetz Bryant , Hoke Nicholas , Dong Ting , Craig David W. , Cristofanilli Massimo , Leyland-Jones Brian , Liotta Lance A. , O'Shaughnessy Joyce A. , Carpten John D. , Petricoin Emanuel F.
Published: April 2023

Proportion of patients with mutation/activation of the PIK3CA-AKT-mTOR pathway in liver metastases compared to other organ sites and primary tumors of the breast.
Supplementary figures 1-2 from Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Authors: Li Gang G. , Somwar Romel , Joseph James , Smith Roger S. , Hayashi Takuo , Martin Leenus , Franovic Aleksandra , Schairer Anni , Martin Eric , Riely Gregory J. , Harris Jason , Yan Shunqi , Wei Ge , Oliver Jennifer W. , Patel Rupal , Multani Pratik , Ladanyi Marc , Drilon Alexander
Published: April 2023

Supplementary Figure 1. In vitro characterization of RET inhibitory activity of RXDX-105 in HBEC3KT-RET cells; Supplementary Figure 2. In vivo efficacy of RXDX-105 in a xenograft model of HBEC3KT-RET harboring CCDC6-RET fusion.
Figure S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Authors: Pierobon Mariaelena , Ramos Corinne , Wong Shukmei , Hodge K. Alex , Aldrich Jessica , Byron Sara , Anthony Stephen P. , Robert Nicholas J. , Northfelt Donald W. , Jahanzeb Mohammad , Vocila Linda , Wulfkuhle Julia , Gambara Guido , Gallagher Rosa I. , Dunetz Bryant , Hoke Nicholas , Dong Ting , Craig David W. , Cristofanilli Massimo , Leyland-Jones Brian , Liotta Lance A. , O'Shaughnessy Joyce A. , Carpten John D. , Petricoin Emanuel F.
Published: April 2023

Concordance between PIK3CA, AKT, and PTEN mutation status and AKT (S473) and p70S6 (T389) activation.
Supplementary figure legends from Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Authors: Li Gang G. , Somwar Romel , Joseph James , Smith Roger S. , Hayashi Takuo , Martin Leenus , Franovic Aleksandra , Schairer Anni , Martin Eric , Riely Gregory J. , Harris Jason , Yan Shunqi , Wei Ge , Oliver Jennifer W. , Patel Rupal , Multani Pratik , Ladanyi Marc , Drilon Alexander
Published: April 2023

Supplementary figure legends
Table S2 from Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase
Authors: Dai Xiaoyang , Yan Juan , Fu Xuhong , Pan Qiuming , Sun Danni , Xu Yuan , Wang Jiang , Nie Litong , Tong Linjiang , Shen Aijun , Zheng Mingyue , Huang Min , Tan Minjia , Liu Hong , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

Supplementary Table S2 shows the effect of aspirin on MDA-MB-231 lung metastasis in vivo
Supplement 2 from Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Authors: Brabander Tessa , van der Zwan Wouter A. , Teunissen Jaap J.M. , Kam Boen L.R. , Feelders Richard A. , de Herder Wouter W. , van Eijck Casper H.J. , Franssen Gaston J.H. , Krenning Eric P. , Kwekkeboom Dik J.
Published: April 2023

Supplement Figure 1. Median overall survival for patients receiving a cumulative dose of {greater than or equal to}100 mCi 177Lu-DOTATATE with a primary NET located in the midgut with and without progression at baseline.
Table S1 from Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase
Authors: Dai Xiaoyang , Yan Juan , Fu Xuhong , Pan Qiuming , Sun Danni , Xu Yuan , Wang Jiang , Nie Litong , Tong Linjiang , Shen Aijun , Zheng Mingyue , Huang Min , Tan Minjia , Liu Hong , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

Supplementary Table S1 shows the list of proteins ID in biotin-aspirin treated sample
Figure S3 from Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase
Authors: Dai Xiaoyang , Yan Juan , Fu Xuhong , Pan Qiuming , Sun Danni , Xu Yuan , Wang Jiang , Nie Litong , Tong Linjiang , Shen Aijun , Zheng Mingyue , Huang Min , Tan Minjia , Liu Hong , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

supplementary Figure S3 shows the inhibiting effect of aspirin on migration and invasion of MDA-MB-231 in vitro and in vivo
Figure S3 from HMGA2–FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer
Authors: Dong Jiaqiang , Wang Rui , Ren Gui , Li Xiaowei , Wang Jingbo , Sun Yi , Liang Jie , Nie Yongzhan , Wu Kaichun , Feng Bin , Shang Yulong , Fan Daiming
Published: April 2023

HMGA2 regulated cell motility and EMT-like molecular alterations. A. Knockdown of HMGA2 suppressed the migration and invasion of chemo-resistant GC cells in vitro. B. Silencing HMGA2 led to increased E-cadherin and decreased vimentin. **P<0.01. C. Knockdown of HMGA2 suppressed the migration and invasion of chemo-resistant GC cells in vivo. **P<0.01. D. GC cells transfected with HMGA2 acquired enhanced migratory and invasive capacities in vitro. E. Ectopic HMGA2 expression induced EMT-like molecular features in GC cells. **P<0.01. F. HMGA2 promoted cell metastasis in vivo. **P<0.01.
Supplementary Table S6 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Authors: Yam Clinton , Xu Xiaowei , Davies Michael A. , Gimotty Phyllis A. , Morrissette Jennifer J.D. , Tetzlaff Michael T. , Wani Khalida M. , Liu Shujing , Deng Wanleng , Buckley Meghan , Zhao Jianhua , Amaravadi Ravi K. , Haas Naomi B. , Kudchadkar Ragini R. , Pavlick Anna C. , Sosman Jeffrey A. , Tawbi Hussein , Walker Luke , Schuchter Lynn M. , Karakousis Giorgos C. , Gangadhar Tara C.
Published: April 2023

Differences in baseline protein expression between patients who did (n=3) and did not (n=3) achieve disease control. A table summarizing the differences in baseline levels of protein expression between patients who achieved disease control and those who did not.
Supplementary Figure S3 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

Change from baseline PD-L1 expression. Data included are for patients with matched fresh tumor biopsies at baseline and cycle 2, day 8 (C2D8) of nivolumab treatment. Each solid line represents a patient. The horizontal dotted line represents 5% PD-L1 expression.
Supplementary Figure S1 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

CONSORT diagram.
Movie 2 from The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages
Authors: Yeh Yu-Min , Hsu Shan-Ju , Lin Peng-Chan , Hsu Keng-Fu , Wu Pei-Ying , Su Wu-Chou , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

CSF-1R endocytosis in macrophage with CSF1R c.1085A_G.
Supplementary Table 1 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Sequence of the primers used to amplify mouse BTLA
Figure S5 from The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages
Authors: Yeh Yu-Min , Hsu Shan-Ju , Lin Peng-Chan , Hsu Keng-Fu , Wu Pei-Ying , Su Wu-Chou , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

CSF-1-induced phosphorylation and endocytosis of CSF-1R in purified macrophages with different CSF1R c.1085 genotypes.
Supplementary Figure 1 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Analysis of the expression of CD8 and BTLA at the RNA level in data from melanoma patients in TCGA.
Movie 2 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Movie 2 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Supplementary Table S3 from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Label-free quantitation of aspartyl proteases.
Supplementary Figure Legend from Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host
Authors: Park James H. , van Wyk Hester , McMillan Donald C. , Quinn Jean , Clark Jennifer , Roxburgh Campbell S.D. , Horgan Paul G. , Edwards Joanne
Published: April 2023

Supplementary Figure Legend
Table S4 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Authors: Erbe Amy K. , Wang Wei , Carmichael Lakeesha , Kim KyungMann , Mendonça Eneida A. , Song Yiqiang , Hess Dustin , Reville Patrick K. , London Wendy B. , Naranjo Arlene , Hank Jacquelyn A. , Diccianni Mitchell B. , Reisfeld Ralph A. , Gillies Stephen D. , Matthay Katherine K. , Cohn Susan L. , Hogarty Michael D. , Maris John M. , Park Julie R. , Ozkaynak M. Fevzi , Gilman Andrew L. , Yu Alice L. , Sondel Paul M.
Published: April 2023

Clinical characteristics of COG patients, according to treatment group, for all patients and for those genotyped for KIR/KIR-ligand.
Sup Fig. 7 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

Densitometry Data for Immunoblots
Supplementary data from Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus
Authors: Ramachandran Mohanraj , Yu Di , Dyczynski Matheus , Baskaran Sathishkumar , Zhang Lei , Lulla Aleksei , Lulla Valeria , Saul Sirle , Nelander Sven , Dimberg Anna , Merits Andres , Leja-Jarblad Justyna , Essand Magnus
Published: April 2023

Supplementary material and methods Supplementary Table 1: miR124, miR125 and miR134 expression relative to human or mouse U6 snRNA in normal mouse CNS tissues, mouse neural stem cells, in vitro-differentiated mouse brain cells, mouse neuroblastoma, human neuroblastoma and in human glioblastoma cell culture (HGCC) lines. Supplementary Table 2: Comprehensive information of HGCC lines used in the experiments Supplementary Figure S1. SFV4-GFPmiRT and A7/74-GFPmiRT are inhibited in the presence of exogenous miR124, miR125 or miR134. Supplementary Figure S2. SFV infection induces killing of human neuroblastoma cell lines. Supplementary Figure S3. Oncolytic efficiency of A7/74miRT in murine tumor models in vitro and in vivo. Supplementary Figure S4. SFV4miRT-mediated killing of HGCC lines in vitro in the presence and absence of IFN-ÃŽÂ².
Supp Tables from MSH2 Loss in Primary Prostate Cancer
Authors: Guedes Liana B. , Antonarakis Emmanuel S. , Schweizer Michael T. , Mirkheshti Nooshin , Almutairi Fawaz , Park Jong Chul , Glavaris Stephanie , Hicks Jessica , Eisenberger Mario A. , De Marzo Angelo M. , Epstein Jonathan I. , Isaacs William B. , Eshleman James R. , Pritchard Colin C. , Lotan Tamara L.
Published: April 2023

Supplementary Tables
Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer
Authors: Guedes Liana B. , Antonarakis Emmanuel S. , Schweizer Michael T. , Mirkheshti Nooshin , Almutairi Fawaz , Park Jong Chul , Glavaris Stephanie , Hicks Jessica , Eisenberger Mario A. , De Marzo Angelo M. , Epstein Jonathan I. , Isaacs William B. , Eshleman James R. , Pritchard Colin C. , Lotan Tamara L.
Published: April 2023

PD-L1 immunostaining in tumors with MSH2 loss. Standard tissue sections of tumors with MSH2 protein loss shows PD-L1 immunolabeling in lymphocytes predominantly (22966), in lymphocytes and focally in tumor cells (61879) and in lymphocytes predominantly (71503). All photomicrographs are reduced from 200x.
Supp Fig S3 from MSH2 Loss in Primary Prostate Cancer
Authors: Guedes Liana B. , Antonarakis Emmanuel S. , Schweizer Michael T. , Mirkheshti Nooshin , Almutairi Fawaz , Park Jong Chul , Glavaris Stephanie , Hicks Jessica , Eisenberger Mario A. , De Marzo Angelo M. , Epstein Jonathan I. , Isaacs William B. , Eshleman James R. , Pritchard Colin C. , Lotan Tamara L.
Published: April 2023

Additional immunostains of the mismatch repair proteins in a formalin fixed and paraffin embedded primary prostate tumor with germline and somatic MSH2 loss from Figure 1. The tumor has bi-allelic inactivation of MSH2 and shows complete loss of nuclear staining for MSH2 and MSH6, while MLH1 and PMS2 are expressed. All photomicrographs are reduced from 200x.
Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer
Authors: Guedes Liana B. , Antonarakis Emmanuel S. , Schweizer Michael T. , Mirkheshti Nooshin , Almutairi Fawaz , Park Jong Chul , Glavaris Stephanie , Hicks Jessica , Eisenberger Mario A. , De Marzo Angelo M. , Epstein Jonathan I. , Isaacs William B. , Eshleman James R. , Pritchard Colin C. , Lotan Tamara L.
Published: April 2023

Validation of MSH2 immunohistochemistry in formalin fixed paraffin embedded prostate cell lines and tumor tissue controls.
Supplementary Figure Legend from KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition
Authors: Cho Soo-Jeong , Yoon Changhwan , Lee Jun Ho , Chang Kevin K. , Lin Jian-xian , Kim Young-Ho , Kook Myeong-Cherl , Aksoy Bülent Arman , Park Do Joong , Ashktorab Hassan , Smoot Duane T. , Schultz Nikolaus , Yoon Sam S.
Published: April 2023

Supplementary Figure Legend
Supplementary Table 4 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
Authors: Flanagan James M. , Wilson Angela , Koo Chail , Masrour Nahal , Gallon John , Loomis Erick , Flower Kirsty , Wilhelm-Benartzi Charlotte , Hergovich Alexander , Cunnea Paula , Gabra Hani , Braicu Elena Ioana , Sehouli Jalid , Darb-Esfahani Silvia , Vanderstichele Adriaan , Vergote Ignace , Kreuzinger Caroline , Castillo-Tong Dan Cacsire , Wisman G. Bea A. , Berns Els MJJ , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Table S4 - Summary Statistics for 8 CpG sites and Annotation
Supplemental legends from Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition
Authors: Quispel-Janssen Josine M. , Badhai Jitendra , Schunselaar Laurel , Price Stacey , Brammeld Jonathan , Iorio Francesco , Kolluri Krishna , Garnett Matthew , Berns Anton , Baas Paul , McDermott Ultan , Neefjes Jacques , Alifrangis Constantine
Published: April 2023

Supplemental legends
Supplementary Table 2 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
Authors: Flanagan James M. , Wilson Angela , Koo Chail , Masrour Nahal , Gallon John , Loomis Erick , Flower Kirsty , Wilhelm-Benartzi Charlotte , Hergovich Alexander , Cunnea Paula , Gabra Hani , Braicu Elena Ioana , Sehouli Jalid , Darb-Esfahani Silvia , Vanderstichele Adriaan , Vergote Ignace , Kreuzinger Caroline , Castillo-Tong Dan Cacsire , Wisman G. Bea A. , Berns Els MJJ , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Table S2 - Pyrosequencing Primers used in this study
Supplementary Table 1 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
Authors: Flanagan James M. , Wilson Angela , Koo Chail , Masrour Nahal , Gallon John , Loomis Erick , Flower Kirsty , Wilhelm-Benartzi Charlotte , Hergovich Alexander , Cunnea Paula , Gabra Hani , Braicu Elena Ioana , Sehouli Jalid , Darb-Esfahani Silvia , Vanderstichele Adriaan , Vergote Ignace , Kreuzinger Caroline , Castillo-Tong Dan Cacsire , Wisman G. Bea A. , Berns Els MJJ , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Table S1 - Patient Characteristics
Supplementary table 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

The predicted targets for hsa-miR-221
Supplementary Table Legends from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Authors: Hanaford Allison R. , Archer Tenley C. , Price Antoinette , Kahlert Ulf D. , Maciaczyk Jarek , Nikkhah Guido , Kim Jong Wook , Ehrenberger Tobias , Clemons Paul A. , Dančík Vlado , Seashore-Ludlow Brinton , Viswanathan Vasanthi , Stewart Michelle L. , Rees Matthew G. , Shamji Alykhan , Schreiber Stuart , Fraenkel Ernest , Pomeroy Scott L. , Mesirov Jill P. , Tamayo Pablo , Eberhart Charles G. , Raabe Eric H.
Published: April 2023

Legends for the supplementary tables
Supplementary figure 4 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

Effects of miR-221 on the mRNA levels of cell cycle genes, including p21, p27, p57, C-MYC, and CCND1 in NB cells.
Supplementary Figure Legends from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Authors: Hanaford Allison R. , Archer Tenley C. , Price Antoinette , Kahlert Ulf D. , Maciaczyk Jarek , Nikkhah Guido , Kim Jong Wook , Ehrenberger Tobias , Clemons Paul A. , Dančík Vlado , Seashore-Ludlow Brinton , Viswanathan Vasanthi , Stewart Michelle L. , Rees Matthew G. , Shamji Alykhan , Schreiber Stuart , Fraenkel Ernest , Pomeroy Scott L. , Mesirov Jill P. , Tamayo Pablo , Eberhart Charles G. , Raabe Eric H.
Published: April 2023

Legends for the supplementary figures
Supplementary figure 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

Assessment of MYCN mRNA expression in human NB cells by qRT-PCR.
Supplemental Figure 4 from Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Authors: Lowenfeld Lea , Mick Rosemarie , Datta Jashodeep , Xu Shuwen , Fitzpatrick Elizabeth , Fisher Carla S. , Fox Kevin R. , DeMichele Angela , Zhang Paul J. , Weinstein Susan P. , Roses Robert E. , Czerniecki Brian J.
Published: April 2023

Supplemental Figure 4: The CD4pos Th1 immune response in the peripheral blood pre-vaccination and post-vaccination by clinical response (
Supplemental Figure 1 from Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Authors: Lowenfeld Lea , Mick Rosemarie , Datta Jashodeep , Xu Shuwen , Fitzpatrick Elizabeth , Fisher Carla S. , Fox Kevin R. , DeMichele Angela , Zhang Paul J. , Weinstein Susan P. , Roses Robert E. , Czerniecki Brian J.
Published: April 2023

Supplemental Figure 1: CONSORT diagram of the 58 patients enrolled in the vaccine trial. A total of 54 were randomized to one of the three vaccination routes. After the twenty second patient completed the vaccine, subsequent ER positive patients were treated with concurrent anti-estrogen therapy.
Supplemental Figures 1-5 from Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer
Authors: Dávila-González Daniel , Choi Dong Soon , Rosato Roberto R. , Granados-Principal Sergio M. , Kuhn John G. , Li Wen-Feng , Qian Wei , Chen Wen , Kozielski Anthony J. , Wong Helen , Dave Bhuvanesh , Chang Jenny C.
Published: April 2023

Supplemental Figure 1. Docetaxel induce the expression of iNOS following a bell shape distribution, no consistent effect is observed on eNOS; Supplemental Figure 2. L-NMMA decreased iNOS and enhances docetaxel toxicity on MDA-MB 468; Supplemental Figure 3. Response to NOS inhibition therapy on TNBC PDXs. Supplemental Figure 4. (A) NOS inhibition mitigates pro-survival pathways activated by docetaxel; Supplemental Figure 5. NOS inhibition therapy enhance apoptotic response; Supplemental Figure 5. NOS inhibition therapy enhance apoptotic response.
Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Authors: Tran Hung C. , Wan Zesheng , Sheard Michael A. , Sun Jianping , Jackson Jeremy R. , Malvar Jemily , Xu Yibing , Wang Larry , Sposto Richard , Kim Eugene S. , Asgharzadeh Shahab , Seeger Robert C.
Published: April 2023

Supplementary Figure S1 shows that expression of natural cytotoxicity receptors and GD2 on neuroblastoma cells are not affected by TGFbeta1 or galunisertib.
Figure S4 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

The effects of miR-34a expression on eEF2K and its downstream targets in TNBC cells.
Supplementary Data from Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging
Authors: Chang Ken , Bai Harrison X. , Zhou Hao , Su Chang , Bi Wenya Linda , Agbodza Ena , Kavouridis Vasileios K. , Senders Joeky T. , Boaro Alessandro , Beers Andrew , Zhang Biqi , Capellini Alexandra , Liao Weihua , Shen Qin , Li Xuejun , Xiao Bo , Cryan Jane , Ramkissoon Shakti , Ramkissoon Lori , Ligon Keith , Wen Patrick Y. , Bindra Ranjit S. , Woo John , Arnaout Omar , Gerstner Elizabeth R. , Zhang Paul J. , Rosen Bruce R. , Yang Li , Huang Raymond Y. , Kalpathy-Cramer Jayashree
Published: April 2023

Supplementary Data
Figure S2 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

Ectopic expression of miR-34a increases relative miR-34a expression levels in control lentiviral and FOXM1 lentiviral transduced TNBC cells.
Supplemental Material 2: Impact of the prevalence of marker-positive patients in the general population on the characteristics of the marker-based designs. from Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design
Authors: Matsui Shigeyuki , Crowley John
Published: April 2023

Impact of the prevalence of marker-positive patients in the general population on the characteristics of the marker-based designs
Supplemental Material 1: Proposed marker-stratified design from Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design
Authors: Matsui Shigeyuki , Crowley John
Published: April 2023

Proposed marker-stratified design
Supplementary Figure 4 from Neoadjuvant Enzalutamide Prior to Prostatectomy
Authors: Montgomery Bruce , Tretiakova Maria S. , Joshua Anthony M. , Gleave Martin E. , Fleshner Neil , Bubley Glenn J. , Mostaghel Elahe A. , Chi Kim N. , Lin Daniel W. , Sanda Martin , Novotny William , Wu Kenneth , Kantoff Philip W. , Marck Brett T. , Plymate Stephen , Balk Steven P. , Nelson Peter S. , Matsumoto Alvin M. , Lis Rosina T. , Kibel Adam , Haas Gabriel P. , Krivoshik Andrew , Hannah Alison , Taplin Mary-Ellen
Published: April 2023

Figure S4. Correlation of immunohistochemical expression of the glucocorticoid receptor (GR) after enza or enza/dut/LHRHa with residual cancer burden (RCB). A tissue microarray comprising cores of cancer tissue from each patient was analyzed for RCB and nuclear expression of GR expressed as total proportion of GR-positive tumor nuclei in (A) enza-treated and (B) enza/dut/LHRHa-treated patients. P values were calculated using the nonparametric Mann-Whitney test.
Supplementary Figure 1 from Neoadjuvant Enzalutamide Prior to Prostatectomy
Authors: Montgomery Bruce , Tretiakova Maria S. , Joshua Anthony M. , Gleave Martin E. , Fleshner Neil , Bubley Glenn J. , Mostaghel Elahe A. , Chi Kim N. , Lin Daniel W. , Sanda Martin , Novotny William , Wu Kenneth , Kantoff Philip W. , Marck Brett T. , Plymate Stephen , Balk Steven P. , Nelson Peter S. , Matsumoto Alvin M. , Lis Rosina T. , Kibel Adam , Haas Gabriel P. , Krivoshik Andrew , Hannah Alison , Taplin Mary-Ellen
Published: April 2023

Residual cancer burden (RCB) from each patient in the (A) enza and (B) enza/dut/LHRHa arms.
Figure S4 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Figure S4. Comparison of EMT-related genes between HEY1 high and low groups using TCGA data
Tim-3+ Treg cells from HNSCC TIL secrete more cytokines. from Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients
Authors: Liu Zhuqing , McMichael Elizabeth L. , Shayan Gulidanna , Li Jing , Chen Kevin , Srivastava Raghvendra , Kane Lawrence P. , Lu Binfeng , Ferris Robert L.
Published: April 2023

For IL-10, Granzyme B and IFN-γ quantification, bulk TIL were stimulated in vitro with anti-CD3/CD28 beads and protein transport inhibitor (BD GolgiPlugTM) for 6h.Cells were then stained for intracellular cytokine expression by flow cytometry. Summary data were showing IL-10 MFI (P>0.05), IL-10 percentage (p=0.0508), IFN-γ (P>0.05), Granzyme B (P<0.01), LAP (P>0.05) and Ki67 (P>0.05) by flow cytometry, gated on Tim-3- Tregs and Tim-3+ Tregs from HNSCC TILs (n=4-11 patients per marker, as indicated).
Figure S2 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Figure S2. NOTCH4 expression in si-NOTCH4 cells. NOTCH activity assay, cisplatin viability assay, apoptosis assay and cell cycle analysis in si-NOTCH4 cells.
Figure S1 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Figure S1. The correlation of NOTCH pathway genes and the HES/HEY high group.
Supplementary Figure Legends from AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
Authors: Scarborough Hannah A. , Helfrich Barbara A. , Casás-Selves Matias , Schuller Alwin G. , Grosskurth Shaun E. , Kim Jihye , Tan Aik-Choon , Chan Daniel C. , Zhang Zhiyong , Zaberezhnyy Vadym , Bunn Paul A. , DeGregori James
Published: April 2023

Supplementary Figure Legends
table 1 b from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental table 1B List of PDX pancreatic samples. Information regarding KRAS-mutation and gemcitabine resistance profile. S for sensitive, R for Resistant.